---
title: "Webinar | PD-L1 on the edge: cut-offs, cognitive bias & the case for AI in lung cancer pathology"
description: Watch this webinar to discover the real-world diagnostic pressure points of PD-L1 TPS testing in NSCLC.
image: https://www.aiforia.com/hubfs/.pixelcompress/Website%20Assets/Webinars/Webinars%20LP%20thumbnails/On-demand%20webinar_PD-L1%20on%20the%20edge_thumbnail.png
---

![](https://www.aiforia.com/hubfs/Avidly2020_Theme_assets/anime/Neural-network-complex-image.svg)

# On-demand webinar PD-L1 on the edge: cut-offs, cognitive bias & the case for AI in lung cancer pathology

PD-L1 TPS is simple in theory—but far more complex in practice. When eligibility for life-changing immunotherapy hinges on a 1% or 50% score, even a 5% margin of error can shift a patient’s path entirely.

This webinar takes you inside the real-world diagnostic pressure points of PD-L1 TPS testing in NSCLC. With insights drawn from clinical research, pathology practice, and oncology decision-making, we examine the human limits of PD-L1 scoring and how AI can sharpen clinical decisions. 

#### What you’ll learn:

- **The 1% that changes everything**  
  Understand how small differences in PD-L1 Tumor Proportion Score (TPS) drastically influence therapy eligibility—and why that’s a clinical pain point.
- **Cut-offs, callouts, and clinical consequences**  
  Explore why the 1% and 50% cut-offs carry outsized impact, and how subtle inconsistencies in interpretation can create major therapeutic divergence.
- **The human factor: why pathologists disagree**  
  Dive into the technical, visual, and psychological reasons manual scoring is prone to variability—especially in borderline cases.
- **Under-called. Over-called. Mis-called.**  
  See how PD-L1 is commonly misestimated in either direction, and how this leads to patient under-treatment or over-treatment.
- **AI to the assist: can algorithms outscore the experts?**  
  Unpack the evidence on how AI is being trained to assist PD-L1 scoring—offering reproducibility, speed, and support in tough calls.
- **Bridging the diagnostic divide**  
  Hear how pathologists and oncologists view PD-L1 differently—and how AI and digital tools may help unify decision-making.

#### Who should watch?

- Pathologists involved in biomarker testing
- Oncologists relying on PD-L1 scores for treatment planning
- Anyone involved in lung cancer diagnostics or therapeutic decision-making

![Richard Doughty__portrait_500x500px](https://www.aiforia.com/hs-fs/hubfs/Website%20Assets/Team%20Portraits/Team%20portraits_500x500px/Richard%20Doughty__portrait_500x500px.png?width=150&name=Richard%20Doughty__portrait_500x500px.png)

**Richard Doughty** Medical Director, Aiforia Technologies

![Rute P_portrait_500x500px](https://www.aiforia.com/hs-fs/hubfs/Website%20Assets/Team%20Portraits/Team%20portraits_500x500px/Rute%20P_portrait_500x500px.jpg?width=150&name=Rute%20P_portrait_500x500px.jpg)

**Rute Pedrosa** Senior Field Application Scientist, Aiforia Technologies

## Watch the on-demand webinar

On-demand webinar

## PD-L1 on the edge: cut-offs, cognitive bias & the case for AI in lung cancer pathology

Intro to Aiforia

00:57

Dr. Doughty's presentation

04:42

Q&A

44:23

 Your browser does not support the video tag.